



HAL
open science

A non-inferiority randomized phase III trial of standard immunotherapy by checkpoint inhibitors vs. reduced dose intensity in responding patients with metastatic cancer: the MOIO protocol study

Gwenaëlle Gravis, Patricia Marino, Daniel Olive, Frederique Penault-Llorca, Jean-Pierre Delord, Clotilde Simon, Assia Lamrani-Ghaouti, Renaud Sabatier, Joseph Ciccolini, Jean-Marie Boher

► **To cite this version:**

Gwenaëlle Gravis, Patricia Marino, Daniel Olive, Frederique Penault-Llorca, Jean-Pierre Delord, et al.. A non-inferiority randomized phase III trial of standard immunotherapy by checkpoint inhibitors vs. reduced dose intensity in responding patients with metastatic cancer: the MOIO protocol study. BMC Cancer, 2023, 23 (1), pp.393. 10.1186/s12885-023-10881-8 . hal-04109560

HAL Id: hal-04109560

<https://amu.hal.science/hal-04109560>

Submitted on 19 Dec 2023

HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.



Distributed under a Creative Commons Attribution 4.0 International License

STUDY PROTOCOL

Open Access



A non-inferiority randomized phase III trial of standard immunotherapy by checkpoint inhibitors vs. reduced dose intensity in responding patients with metastatic cancer: the MOIO protocol study

Gwenaelle Gravis^{1*}, Patricia Marino², Daniel Olive³, Frederique Penault-LLorca⁴, Jean-Pierre Delord⁵, Clotilde Simon⁶, Assia Lamrani-Ghaouti⁶, Renaud Sabatier³, Joseph Ciccolini⁷ and Jean-Marie Boher⁸

Abstract

Background Immunotherapy (IO) has become a standard of care for treating various types of metastatic cancers and has significantly improved clinical outcome. With the exception of metastatic melanoma in complete response for which treatment can be stopped at 6 months, these treatments are currently administered until either disease progression for some IO, 2 years for others, or unacceptable toxicity. However, a growing number of studies are reporting maintenance of response despite discontinuation of therapy. There is currently no evidence of a dose effect of IO in pharmacokinetic studies. Maintaining efficacy despite a reduction in treatment intensity by decreasing the frequency of administration in patients with highly selected metastatic cancer, is the hypothesis evaluated in the MOIO study.

Method/design This non-inferiority, randomized phase III study aims to compare the standard regimen to a 3 monthly regimen of various IO drugs in adult patients with metastatic cancer in partial (PR) or complete response (CR) after 6 months of standard IO dosing (except melanoma in CR). This is a French national study conducted in 36 centers. The main objective is to demonstrate that the efficacy of a three-monthly administration is not unacceptably less efficacious than a standard administration. Secondary objectives are cost-effectiveness, quality of life (QOL), anxiety, fear of relapse, response rate, overall survival and toxicity.

After 6 months of standard IO, patients with partial or complete response will be randomized 1:1 between standard IO or a reduced intensity dose of IO, administered every 3 months. The randomization will be stratified on therapy line, tumor type, IO type and response status. The primary endpoint is the hazard ratio of progression-free survival. With a planned study duration of 6 years, including 36 months enrolment time, 646 patients are planned to demonstrate with a statistical level of evidence of 5% that the reduced IO regimen is non-inferior to the standard IO regimen, with a relative non-inferiority margin set at 1.3.

*Correspondence:

Gwenaelle Gravis
gravisg@ipc.unicancer.fr

Full list of author information is available at the end of the article



© The Author(s) 2023. **Open Access** This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <http://creativecommons.org/licenses/by/4.0/>. The Creative Commons Public Domain Dedication waiver (<http://creativecommons.org/publicdomain/zero/1.0/>) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

Discussion Should the hypothesis of non-inferiority with an IO reduced dose intensity be validated, alternate scheduling could preserve efficacy while being cost-effective and allowing a reduction of the toxicity, with an increase in patient's QOL.

Trial registration NCT05078047.

Keywords Metastatic cancer, Immunotherapy, Checkpoint inhibitors, Health Economics, Quality of life

Introduction

The number of approved immune-oncological agents (IO) such as PD-1/PD-L1 and CTLA-4 inhibitors is increasing. Their rhythm and duration of treatment are recommended until either disease progression for some IO, 2 years for other or unacceptable toxicity. However, there are still some unresolved questions about the administration schemes of IO.

First, the optimal duration of immune checkpoint inhibitors (ICIs) is currently unknown. Complete response (CR) before therapy discontinuation is shown to be a positive factor for a prolonged response as shown in the KEYNOTE-001 & 006 trials [1, 2]. To date it is not clear whether continuous immunotherapy treatment should be given to responding patients until disease progression, since stable responses and long survivals have also been reported in patients in whom immunotherapy had been discontinued months before, with an actual survival plateau observed in melanoma, non-small cell lung cancer (NSCLC) and renal cell cancer [3, 4]. This durability of the response is currently explained by the theoretical rationale that anti-PD-L1 therapy can generate a mono or polyclonal and memory adaptive T-cells anti-tumor immunity, either CD45 or CD86 that is able to control the heterogeneity of the disease and to reset the tumor-host immune interaction toward cancer rejection [5].

Second, the minimal duration of ICIs is also currently unknown. The Evidence from current clinical trials in different tumor types indicates that most of the responses are generally occurring early, with a median time of 2–4 months. In patients with CR, the risk of progression was significantly higher in those treated for <6 months compared with those treated for >6 months [6]. Check-Mate153 that compared continuous *versus* 1-year immunotherapy in previously treated advanced NSCLC in partial or complete response, or in stable disease, suggested that continuing nivolumab beyond 1 year improved outcomes [7].

The frequency of administration has been arbitrary defined by clinical trials. The optimal dose of IO remains unknown. No major dose-dependent effect of anti-PD-1 has been observed, and whether the frequency of infusion of IO could improve response or maintain efficacy is unclear. Moreover, phase I studies have shown that

saturation of the target (PD-1 or PD-L1) can persist far beyond the serum half-life of the IO and 3-monthly infusions of an anti-PD-1 antibody could potentially generate the same level of activity as infusions administered every 2 weeks [8]. In silico modelling studies have suggested that alternate scheduling with IO would not compromise treatment efficacy. Indeed, prolonged half-lives of IO drugs, time-varying clearance plus plasma concentrations far above the threshold associated with maximal target-engagement, suggest that the rhythm of administration of IO could be slowed down [9–12].

In a context where over-treatment with ICIs may be toxic, inefficient [13] and cost-ineffective [14], a prospective analysis of progression-free survival and overall survival between continuous treatment *versus* reduction treatment without discontinuation is an alternative that needs to be evaluated. This therapeutic alternative may provide less drug-related SAEs, with better quality of life and reduced treatment costs.

MOIO is a randomized phase III study comparing the standard administration of IO *versus* the same IO administered every 3 months in patients with metastatic cancer in partial or complete response after 6 months of approved standard IO (except melanoma in complete response).

Methods & design

Study design

Sponsored by the French national network of anticancer centers (UNICANCER), MOIO is a national, multicenter, randomized, controlled, open label Phase 3 trial comparing a reduced dose intensity of IO *versus* approved standard IO regimen in patients with metastatic oncologic tumor in complete or partial response after 6 months of treatment with standard IO. Study protocol has been approved by the Institutional Review Board (IRB) of UNICANCER.

Study objectives

The primary objective of the trial is to demonstrate the non-inferiority in terms of PFS of administration of reduced dose intensity of IO *versus* standard IO for patients in response after 6 months of standard IO.

Secondary objectives are to evaluate:

- Cost-effectiveness,
- The efficacy in terms of:
 - Immune progression-free survival using iRECIST,
 - Objective response rate at 12 and 24 months post-randomization,
 - Overall survival,
 - Duration of response at 12 months post-randomization,
- Quality of life (self-reported EORTC QLQ-C30 and EQ-5D-5L questionnaires),
- Anxiety and fear of relapse using specific questionnaires,
- Safety profile.

Primary endpoint

The primary outcome is progression-free survival (PFS) calculated from the date of randomization to the date of first progression or death from any cause, whichever occurs first. Progression will be determined locally by the investigator through the use of RECIST v1.1 in case of lesions identified at baseline. For patients without any evidence of disease at inclusion, the progression will be defined as an appearance of a new lesion (measurable or not measurable). Patients who have not progressed or died at the time of analysis will be censored at the time of the latest date of RECIST assessment.

In case of initiation of subsequent anticancer therapy before disease progression or death, patients will be censored on the date of first initiation of subsequent anticancer therapy.

Secondary endpoints

The secondary outcomes are:

- Incremental cost-effectiveness ratio (ICER) expressed as a cost per quality-adjusted life year (QALY) gained at 36 months.
- Efficacy
 - Immune progression-free survival (iPFS) calculated from the date of randomization to the date of disease progression or death from any cause, whichever occurs first. Immune progression will be determined locally by the investigator according to iRECIST v1.1 in case of lesions identified at baseline.
 - Objective response rate (ORR) defined as the percentage of patients with a confirmed complete response (CR) or partial response (PR) at 12 and 24 months post-randomization considering patients who switch from study treatment to any other cancer treatment within 12 and 24 months post-randomization as failures.
 - Overall survival (OS) calculated from the date of randomization to the date of death from any cause.
 - Duration of response (DoR) defined as the time from randomization to first documented disease progression or death, whichever occurs first.
 - Quality of life mean score of self-reported EORTC QLQ-C30 and EQ-5D-5L questionnaires at inclusion visit (pre-randomization), 3, 6, 9, 12, 15, 18, 24 and 36 months post-randomization.
 - Evaluation of anxiety and fear of recurrence scores using specific questionnaires (HADS and Fear of Cancer Recurrence Inventory, Short Form) at 3, 6, 9, 12, 15, 18, 24 and 36 months post-randomization.
 - Number, frequency and severity of adverse events according to CTCAE v5.0 at 12 months and 3 years post-randomization.

Ancillary studies of pharmacokinetics, immuno-monitoring and ctDNA will be conducted to determine biomarkers (at the immune and genomic levels) that can identify patients that would benefit from dose reduction.

Study population

Prior to enrollment, all participants will be screened to check their inclusion and exclusion criteria (Table 1).

Inclusion criteria

Eligible patients should have a histologically confirmed metastatic disease (lung cancer, renal cell cancer, head and neck cancer, bladder cancer, triple negative breast cancer, Merkel cancer, hepatocellular carcinoma, melanoma, colorectal carcinoma with microsatellite instability (MSI) or esophageal squamous cell carcinoma). Patients with brain metastases are allowed, provided they are stable (treated with surgery or stereotactic radiosurgery and without evidence of progression prior to randomization and have no evidence of new or enlarging brain metastases). Patients should be in partial or complete response after 6 months of standard immunotherapy (whatever the line of therapy). For metastatic melanoma, only patients in partial response will be eligible. Patients treated in the first 6 months by IO alone or in combination with other IO, chemotherapy or tyrosine kinase inhibitor (TKI) are also allowed. Patient must be 18 years or older, have a good general health status (ECOG \leq 1), eligible to maintain the same standard IO treatment, and provide a signed informed consent form before study entry.

Table 1 Eligibility criteria for the study population

Inclusion criteria	Exclusion criteria
<ol style="list-style-type: none"> 1. Patient must have signed a written informed consent form prior to any trial specific procedures 2. Patient aged ≥ 18 years old 3. Initial metastatic disease histologically confirmed including: lung cancer, renal cell cancer, head and neck cancer, bladder cancer, triple negative breast cancer, Merkel cancer, hepatocellular carcinoma, melanoma, colorectal carcinoma with microsatellite instability [MSI], or esophageal squamous cell carcinoma 4. Patients in partial or complete response after 6 months of standard immunotherapy (whatever the line of therapy) according to the RECIST criteria (confirmed by local radiological assessment). For metastatic melanoma only patients in partial response 5. Eligible to maintain the same standard IO treatment 6. Patient with ECOG performance status ≤ 1 7. Patients with brain metastases are allowed, provided they are stable according to the following definitions: treated with surgery or stereotactic radiosurgery and without evidence of progression prior to randomization and have no evidence of new or enlarging brain metastases 8. Patients treated by IO previously combined with chemotherapy are allowed 9. Patients with TKI-IO or pemetrexed-IO or bevacizumab-IO are allowed 10. Evidence of post-menopausal status, negative urinary, or serum pregnancy test for female pre-menopausal patients 11. Both sexually active women of childbearing potential and males (and their female partners) patients must agree to use adequate contraception method for the duration of the study treatment and after completing treatment according to the most recent version of the IO SmPC 12. Patient is willing and able to comply with the protocol for the duration of the trial including undergoing treatment and scheduled visits, and examinations including follow-up 13. Patient must be affiliated to a Social Security System 	<ol style="list-style-type: none"> 1. Metastatic melanoma in complete response 2. Metastatic renal cell carcinoma with IMDC favourable-risk treated TKI/IO combination 3. Hematologic malignancies (leukaemia, myeloma, lymphoma...) 4. Active infection requiring systemic therapy 5. Patients enrolled in another therapeutic study within 30 days before the inclusion in and during MOIO study 6. Patient unable to comply with study obligations for geographic, social, or physical reasons, or who is unable to understand the purpose and procedures of the study 7. Person deprived of their liberty or under protective custody or guardianship

Exclusion criteria

Patients are not eligible to participate in the trial if they have metastatic melanoma in complete response, metastatic renal cell carcinoma with IMDC favorable-risk treated TKI/IO combination, or hematologic malignancies (leukemia, myeloma, lymphoma...).

Randomization

Eligible patients will be randomized 1:1 to:

1. *Experimental arm*: Reduced dose intensity of IO

IO will be administered every 3 months (at the same dose levels) until disease progression, unacceptable toxicity, death, patient's choice or investigator's decision.

2. *Control arm*: Standard IO

Continuation of IO at the same dose levels and rhythmicity until disease progression, unacceptable toxicity, death, patient's choice or investigator's decision.

The randomization will be stratified by:

- Response (CR vs PR),

- Metastatic tumor type (lung cancer, renal cell cancer, head and neck cancer, bladder cancer, triple negative breast cancer, Merkel cancer, hepatocellular carcinoma, melanoma, colorectal carcinoma with microsatellite instability [MSI], or esophageal squamous cell carcinoma).
- IO type (anti-PD-1 vs anti-PD-L1),
- Treatment line (first line vs others).

Trial design is shown in Fig. 1.

Treatment plan**Therapeutic regimens**

Patient treatment will consist of immunotherapy with PD-1 or PD-L1 antagonists to be used in monotherapy or in combination (with other immunotherapy [ipilimumab] or chemotherapy or continuous combination with pemetrexed, bevacizumab or TKI), within their marketed indication and according to most recent version of the Summary of Product Characteristics (SmPC) of each product (Table 2).

Treatment should be administered and adjusted and toxicities managed in both arms according to the most recent version of the IO SmPC recommendations and local practice.




Fig. 1 Trial scheme of the MOIO clinical trial

Table 2 Product name and administration

Drug name (INN)	Registered name ^(a)	Administration route	Posology
Nivolumab	OPDIVO	IV	According to the most recent version of the SmPC
Pembrolizumab	KEYTRUDA	IV	According to the most recent version of the SmPC
Durvalumab	IMFINZI	IV	According to the most recent version of the SmPC
Atezolizumab	TECENTRIQ	IV	According to the most recent version of the SmPC
Avelumab	BAVENCIO	IV	According to the most recent version of the SmPC

INN International non-proprietary name, SmPC Summary of product characteristics

^a When any generic drug can be used indicate only the INN Name. The choice of the registered name or brand name used in the trial is at the investigation center discretion

Duration of treatment

Treatment duration will be 36 months maximum or until disease progression, unacceptable toxicity, death, patient’s choice or investigator’s decision.

Visit schedule and assessments (Supplementary Table 1)

MOIO patients treated with IO in both arms will have a follow-up during 36 months post-randomization. This first visit take place immediately after randomization.

During the treatment and follow up periods, patients in both arms will have a trial visit every 3 months (± 7 days). However, depending on treatment tolerance, additional visits may be scheduled as per standard of care. All examinations revealing a toxicity related to IO treatment must be periodically repeated until toxicity disappearance (or until it is deemed irreversible) as per standard of care. The last visit corresponding to the end of MOIO study will be done 36 months post randomization.

Adverse events

All AE, irrespective of seriousness, will be collected from the day of randomization to the follow-up visit/end of trial visit at the time points specified in the trial visits schedule.

Each AE associated with treatment in both arms will be classified using the NCI-CTCAE v5.0 classification.

Statistical analysis

Sample Size calculation

Given a HR of 1.3 as the non-inferiority margin, 498 progressions or deaths are necessary to establish the non-inferiority in PFS of the experimental arm *versus* the control with 5% level of significance and 90% power assuming no difference between arms (HR = 1).

Assuming 22-month median PFS in both arms, 36-month accrual period, 72-month study duration and a 5% lost to follow-up rate, a total of 646 patients is planned.

The final analysis is scheduled 3 years after the last patient randomization.

Statistical analyses

The assessment of efficacy will be based primarily on a per-protocol (PP) population consisting of all randomized patients, except those who did not adhere to the study treatment for reasons of personal convenience, which could make the treatment groups appear similar. Other analyses will be based on a modified intention-to-treat population (mITT) consisting of all randomized patients, except patients who were deemed ineligible after randomization or patients who never started treatment. Prior to analysis, exclusion from PP and mITT populations will be reviewed by an independent data monitoring committee. Unless otherwise specified, the parameters will be estimated with 95% confidence intervals and missing data will not be replaced.

Analysis of the primary outcome

The primary analysis will seek to evidence non-inferiority in PFS of the experimental arm *versus* the active control arm on the per protocol population.

The PFS data will be summarized in each treatment arm using Kaplan–Meier methods. The analysis will be based on a Cox proportional hazards model including terms for the randomized arm, the tumor type, the IO type (anti-PD-1 vs anti-PD-L1), the therapy line (1st line vs others) and the response status 6 months after initiation of standard IO.

Non-inferiority in PFS will be evaluated on the per protocol set. Cox's regression analyses including terms for randomization factors will be used to estimate the hazard ratio for treatment arm (reduced IO vs standard IO) with 90% confidence interval. Non-inferiority will be declared if the upper bound of the 90% bilateral confidence interval is lower than the predefined non-inferiority margin. In case of non-adherence to the study treatment, a secondary analysis will be conducted on the modified ITT set. Following CPMP guidelines, non-inferiority will be claimed if both analyses lead to similar conclusions.

Interim analysis

In order to minimize the number of patient exposed to an inferior treatment, an independent data monitoring committee will review the efficacy data to stop the trial early for lack of efficacy (harm or futility reasons). Two interim analyses are planned when 25% ($n=125$) and 50% ($n=249$) of the total planned number of events ($n=498$) occurs. At each interim time, a simple and intuitive approach will recommend to stop the trial if the one-sided p -value for testing the hypothesis $HR=1$ *versus* the alternative $HR>1$ is less than 0.0192 (p -value associated to an observed $HR=1.3$ at mid-trial) [15].

Analysis of secondary outcomes

- Cost-effectiveness

The endpoint of the economic analysis will be incremental cost-effectiveness ratio (ICER) which defines the cost per quality-adjusted life years (QALYs). QALYs will be estimated from OS and Progression-free survival PFS by weighting each mean survival time by a utility value (ranging from 0 to 1) derived from the EQ-5D-5L questionnaire. Cost-effectiveness acceptability curves, which give an estimate of the probability that the reduced-dose strategy is cost-effective given various values of society's willingness to pay, will be computed. Unadjusted mean differences in costs and QALYs between the treatment groups will be reported with associated 95% confidence intervals. Tests used for comparisons will be chosen depending on the normality or not of cost data distribution. Comparison of QALYs between groups will be computed by using bilateral logrank tests. To capture longer-term expected costs, outcomes and

cost-effectiveness, in a secondary analysis a simulation model will be developed over a 10-year horizon using a probabilistic Markov model. The transition probabilities between patient's health states (toxicity, stable disease, progression, death) will be obtained both from the study and from the available literature at the date of analysis.

- iPFS, DoR and ORR will be analyzed on the PP and the mITT population. Efficacy time-to-event outcomes will be censored on the date of last known follow up visit. In case of initiation of subsequent anticancer therapy before disease progression or death, individual iPFS and DoR data will be censored on the date of first initiation of subsequent anticancer therapy.
- ORR at 12 and 24 months post-randomization are defined as the percentage of patients with a confirmed CR or PR by considering patients who switch from study treatment to any other cancer therapy within 12 and 24 months post-randomization as treatment failures.
- Time-to-event outcomes will be summarized using Kaplan–Meier methods. Regression models with terms for the randomized arm, the tumor type, the IO type (anti-PD-1 vs anti-PD-L1), the therapy line (1st line vs others) and the response status 6 months after initiation of standard IO will be used to estimate the treatment effect (reduced IO vs standard IO) on secondary efficacy endpoints. Hazard ratios for iPFS, DoR and OS and odds ratio for ORRs will be estimated using Cox's or logistic regression modelling, respectively.
- Analyses of self-reported questionnaires will be based on the mITT population set. Actual values and changes from pre-randomization visit in EORTC QLQ-C30, EQ-5D-5L, anxiety (Hospital Anxiety and Depression Scale) and fear of relapse. (Fear of Cancer Recurrence inventory short Form) specific questionnaires will be tabulated by treatment group using standard descriptive statistics. Differences in changes from pre-randomization visit between treatment arms will be estimated at specific time visit using robust linear regression methods for longitudinal data.

Data management and monitoring

An independent data monitoring committee (IDMC) with expertise and experience in immunotherapy, and without direct involvement in the conduct of the trial, will be set up specifically to guarantee:

- Effective protection of patients.

- Insure the ethical conduct of the trial.
- Benefit/risk ratio of the trial.
- Ensure the independent review of the scientific results during the trial and at the end of the trial.

The IDMC will be composed of at least two oncologists, a health economist and a statistician.

In order to minimize the number of patient exposed to an inferior treatment, the IDMC will review the efficacy data to stop the trial early for lack of efficacy (harm or futility reasons).

Two interim analyses will be planned and presented to the IDMC:

- First analysis when 125 events are observed.
- Second analysis when 249 events are observed.

The IDMC may recommend the early termination of the trial if one of the following conditions is met:

- The results of the interim analysis clearly show that the one-sided P-value for testing the hypothesis $HR=1$ versus the alternative $HR>1$ is less than 0.0192 (p value associated to an observed $HR=1.3$ at mid-trial);
- An unacceptable toxicity.

Database management will be provided by an electronic case report form (eCRF) developed using the CSOnline module of Ennov Clinical[®] software. Patients' individual data are strictly confidential and will be available only to investigators and some defined authorized persons.

Discussion

For approved immunotherapies, such as PD-1/PD-L1 inhibitors and anti-CTLA-4 agents, treatments are administered until disease progression or unacceptable toxicity, with the exception of metastatic melanoma in complete response for which treatment can be stopped at 6 months. However, the optimal dose, frequency and duration of these therapies are currently unknown and a growing number of studies are reporting maintenance of response despite discontinuation of therapy or extension of IO dose intervals [16, 17]. The PRIMIS trial, a phase II in metastatic renal cell cancer presented at ESMO meeting 2021, has shown that extending treatment intervals of immunotherapy did not compromise efficacy and reduced toxicity [16]. A Phase II study in Merckel and metastatic melanoma explored reduced frequency dosing of anti-PD1 with significant efficacy and reduced logistical and financial burden [17].

The interval of treatment

One of the challenges in the field of oncology is knowing how and when to de-escalate immunotherapy and to safely identify patient candidate to de-escalation. MOIO is a pragmatic and strategic study that compares for the first time in a randomized phase III study standard IO administration to the same agent administered every three months in patients with metastatic cancer in in partial or complete response after 6 months of IO (excluding melanoma patients in complete response).

We choose a non-inferiority study because it is the best way to demonstrate that de-escalation is not unacceptably less effective than standard IO scheduling. The population is highly selected and is limited to patients who are in partial or complete response after 6 months of standard IO alone or in combination with other treatments (TKI or chemotherapy).

Cost-effectiveness studies have shown contradictory results about efficiency of checkpoint inhibitors in various type of cancer [14, 18–20]. The possibility of de-escalating cancer treatments by reducing the duration, frequency, dose or number of therapies administered can be seen as an efficient way to optimize patient outcomes efficiently [21]. With the escalating price of cancer drugs [22] and healthcare expenses largely attributable to expensive drugs, the cost of treatment is an important consideration in clinical management decisions [23, 24] and increasing treatment access especially in low-income countries [25]. The cost-effectiveness analysis is therefore an important secondary objective in the MOIO study. While available studies evaluating the efficiency of IO focus on specific localizations, the originality of the MOIO study is to analyze a de-escalation strategy and its economic impact in a multi-disease context.

Beyond the cost-effectiveness of de-escalation strategies, quality of life and patients' wellbeing is an important issue for cancer treatment decisions. Chronic administration of IO generates a significant burden for patients due to the risk of dose-dependent adverse effects, entailing multiple clinic visits and the risk of chronic, life changing and sometimes life-threatening immune mediated toxicities [26, 27]. Optimal dosing of these agents is therefore especially important to maintain patient's quality of life while maintaining good clinical outcome. Consequently, a formal prospective QOL assessment is a secondary objective of the MOIO study. Increasing quality of life and reducing toxicity may have positive consequences on treatment compliance in the longer term.

Fear of disease recurrence may be a barrier to de-escalation clinical trials. This is one of the reasons why a reduced frequency of administration was preferred to treatment discontinuation. However, in the context of little available prospective data on efficacy, patients and

physicians may be afraid to decrease drug dose intensity for fear of tumor progression. In particular, a risk is that patients think they are being undertreated and that the treatment choices are guided by financial rather than medical considerations. It is also established that fear of cancer recurrence is associated with impaired mental quality of life [28, 29]. Thus, we decided, using validated tools, to also assess recurrence of distress and anxiety using patient reported outcomes in the MOIO study.

Conclusion

Many questions remain unanswered about the dose, frequency and duration of administration of immunotherapy by immune check -point inhibitors, particularly in this very sensitive population with a very good response. De-escalation strategies have multiple potential benefits, including reduced toxicity, improved quality of life, improved cost-effectiveness, and better compliance with therapy while maintaining good clinical outcomes. If the non-inferiority hypothesis is demonstrated in the French MOIO study, the use of reduced dose of IO could be practice changing and become the new standard of care for very good responder's patients.

Abbreviations

CAGR	Compound annual growth rate
AE	Adverse event
CR	Complete response
CTCAE	Common terminology criteria for adverse events
DoR	Duration of response
ECOG	Eastern cooperative oncology group
eCRF	Electronic case report form
EORTC	European organization for research and treatment of cancer
HADS	Hospital Anxiety and Depression Scale
HR	Hazard ratio
ICER	Incremental Cost-Effectiveness Ratio
ICIs	Immune checkpoint inhibitors
IDMC	Independent data monitoring committee
IO	Immunotherapy
IRB	Institutional Review Board
iPFS	Immune progression-free survival
iRECIST	Immune Response evaluation criteria in solid tumours
ITT	Intent-to-treat
mITT	Modified intent-to-treat population
ORR	Overall response rate
OS	Overall survival
PD	Progressive disease
PD-1	Programmed cell-death-1
PD-L1	Programmed cell death ligand 1
PP	Per protocol
PR	Partial response
PFS	Progression-free survival
QALY	Quality-adjusted life years
QLQ	Quality of Life Questionnaire
QOL	Quality of life
RECIST	Response evaluation criteria in solid tumours
SAE	Serious adverse event
SD	Stable disease
SmPC	Summary of product characteristics
TKI	Tyrosine Kinase Inhibitor

Supplementary Information

The online version contains supplementary material available at <https://doi.org/10.1186/s12885-023-10881-8>.

Additional file 1: Supplementary Table 1. Schedule of visits.

Acknowledgements

We thank the Unicancer R&D team involved in the preparation/conduct of this study. We also thank Lilian Amrein who provided reviewing and editing services on behalf of Unicancer.

We Thank the French Unicancer Immuno-Oncology Group (GIO) and Urogenital Tumor Study Group (GETUG) for their endorsement.

Authors' contributions

All authors were substantially involved in the conception and design of this study. The coordination is provided by GG, CS and ALG. GG, PM and JMB drafted the manuscript with all other authors contributing to its critical review and approving the final draft. All authors have read and approved the submitted version.

Funding

This research was supported by a grant from the French National Cancer Institute (INCa) in 2020 (PHRC-K 2020–150).

Availability of data and materials

Not applicable.

Declarations

Ethics approval and consent to participate

The trial will be conducted in accordance with the French national regulatory requirements. Study protocol has been approved by the Institutional Review Board (IRB) of UNICANCER. The trial has been registered on Clinicaltrials.gov (NCT05078047).

The trial has been approved by the French Committee for the protection of the persons (Comité de Protection des Personnes, CPP).

The patients/participants provided their written informed consent to participate in this study.

Consent for publication

Not applicable (this manuscript does not contain individual data).

Competing interests

GG: Speaker bureau: Janssen, Amgen, BMS, IPSEN, AAA, Astra Zeneca, Bayer, Pfizer Merck, Astellas. Recipient: my institution.

Board: Janssen, Amgen, BMS, Curium, Bayer, Pfizer Merck. Recipient: my institution.

Expert: BMS, Bayer, Pfizer/ merck. Recipient: my institution.

Travel expense: Janssen, BMS, Astra Zeneca, Bayer, Pfizer Merck. Recipient: me.

FPL: Abbvie, Advisory Board, Personal, DLL3 PARPi Agendia, Invited Speaker, Personal, mammaprint and Blue Print AMGEN, Advisory Board, Personal, biomarkers in lung cancer amgen, Invited Speaker, Personal, educational session biomarkers in lung cancer astellas, Advisory Board, Personal, biomarkers in gastric cancer AstraZeneca, Advisory Board, Institutional, Strategy AstraZeneca, Advisory Board, Personal, HRD, BRCA, HER2low AstraZeneca, Invited Speaker, Personal, HRD, BRCA, HER2 low Bayer, Advisory Board, Personal, NTRK Bayer, Invited Speaker, Personal, NTRK symposium BMS, Invited Speaker, Personal, Symposium IO BMS, Advisory Board, Personal, Immunotherapy pan t Daiichi Sankyo, Advisory Board, Personal, HER2 low Daiichi Sankyo, Invited Speaker, Personal, HER2 low Eisai, Invited Speaker, Personal, Training prof breast cancer exact science, Invited Speaker, Personal, webinar on TailorX gilead, Invited Speaker, Personal, training of Gilead employees on biomarkers in BC and symposia on Biomarkers in TNBC Gilead, Advisory Board, Personal, biomarkers in TNBC GSK, Advisory Board, Institutional, Endometrial cancer Illumina, Invited Speaker, Personal, ESMO symposium Illumina, Advisory Board, Personal, NGS Janssen, Invited Speaker, Institutional, hospitalization at home Janssen, Invited Speaker, Personal, Training prof breast cancer Lilly, Advisory Board, Personal, Ret & breast cancer Lilly, Invited Speaker, Personal, RET & breast cancer

prognosis and biomarker Lilly, Advisory Board, Institutional, Strategy MSD, Invited Speaker, Personal, Immunotherapy BRCA MSD, Advisory Board, Personal, Symposium preparation Novartis, Advisory Board, Personal, PIK3CA and biomarkers in general Novartis, Invited Speaker, Personal, PIK3CA Pfizer, Advisory Board, Personal, ER + breast cancer Pfizer, Invited Speaker, Personal, BRCA breast cancer, ER + BC, biomarkers in lung cancer Pierre Fabre, Invited Speaker, Personal, HER2 breast cancer Pierre Fabre, Advisory Board, Personal, Neratinib Roche, Advisory Board, Personal, Ventana NTRK PD-L1 Roche, Invited Speaker, Personal, FMI test, biomarkers in lung cancer Roche, Other, Institutional, Clinical trial pathology form review sanofi, Advisory Board, Personal, biomarkers in CRC seagen, Advisory Board, Personal, HER2 breast cancer seagen, Invited Speaker, Personal, her2 breast cancer servier, Advisory Board, Personal, biomarkers in cholangiocarcinoma Bayer, Research Grant, Institutional, NTRK testing daiichi sankyo, Local PI, Institutional, RetroBC HER2 low study Nanostring, Research Grant, Institutional, GEOMX breast TNBC.

JPD: BMS, Advisory Board, Institutional Merck Serono, Invited Speaker, Institutional MSD, Advisory Board, Institutional Pierre Fabre, Advisory Board, Institutional Roche, Advisory Board, Institutional Amgen, Research Grant, Institutional, No financial interest Astra Zeneca, Research Grant, Institutional, No financial interest BMS, Research Grant, Institutional, No financial interest Genentech, Research Grant, Institutional, No financial interest MSD, Research Grant, Institutional, No financial interest Transgene, Research Grant, Institutional, No financial interest.

RS: research grant from Astra-Zeneca, consulting fees from GSK, advisory boards from BMS, Clovis, Eisai, and Novartis.

DO is cofounder and shareholder of Imcheck Therapeutics, Emergence Therapeutics, Alderaan Biotechnology and Stealth IO.

The remaining authors have no conflicts of interest to declare.

Author details

¹Department of Medical Oncology, Institut Paoli-Calmettes, Aix-Marseille University, CRCM, Marseille, France. ²Institut Paoli-Calmettes SESSTIM UMR 1252, INSERM, Aix Marseille University, Marseille, France. ³Institut Paoli Calmettes, Aix Marseille Université, CRCM, Inserm U1068, Marseille, France. ⁴Centre Jean Perrin, Université Clermont Auvergne, INSERM, U1240 Imagerie Moléculaire Et Stratégies Théranostiques, Clermont Ferrand, France. ⁵Institut Claudius Regaud IUCT Oncopole, Toulouse, France. ⁶Unicancer R&D, Paris, France. ⁷AP-HM Inserm U1068, Marseille, France. ⁸Department of Biostatistics and Methodology, Institut Paoli Calmettes, and Aix-Marseille University, Unité Mixte de Recherche S1252, Institut de Recherche Pour Le Développement, 13009 Marseille, France.

Received: 20 February 2023 Accepted: 24 April 2023

Published online: 02 May 2023

References

- Robert C, Ribas A, Hamid O, Daud A, Wolchok JD, Joshua AM, et al. Durable complete response after discontinuation of Pembrolizumab in patients with metastatic melanoma. *J Clin Oncol*. 2018;36(17):1668–74. <https://doi.org/10.1200/JCO.2017.75.6270>.
- Long GV, Schachter J, Ribas A, Arance AM, Grob JJ, Mortier L, et al. 4-year survival and outcomes after cessation of pembrolizumab (pembro) after 2-years in patients (pts) with ipilimumab (ipi)-naive advanced melanoma in KEYNOTE-006. *J Clin Oncol*. 2018;Abstract 36:9503–9503.
- McDermott DF, Rini BI, Motzer RJ, Tannir NM, Escudier B, Kollmannsberger CK et al. Treatment-free interval (TFI) following discontinuation of first-line nivolumab plus ipilimumab (N+I) or sunitinib (S) in patients (Pts) with advanced renal cell carcinoma (aRCC): CheckMate 214 analysis. *Annals Oncol*. 2018;29(Supplement 8). <https://doi.org/10.1093/annonc/mdy283.083>. ESMO Abstract.
- Brahmer JR, Lee JS, Ciuleanu TE, Caro RB, Nishio M, Urban L, Audigier-Vallette C, Lupinacci L, Sangha R, Pluzanski A, Burgers J, Mahave M, Ahmed S, Schoenfeld AJ, Paz-Ares LG, Reck M, Borghaei H, O'Byrne KJ, Gupta RG, Bushong J, Li L, Blum SI, Eccles LJ, Ramalingam SS. Five-Year Survival Outcomes With Nivolumab Plus Ipilimumab Versus Chemotherapy as First-Line Treatment for Metastatic Non-Small Cell Lung Cancer in CheckMate 227. *J Clin Oncol*. 2022;101200JCO2201503. <https://doi.org/10.1200/JCO.22.01503>. Epub ahead of print. PMID: 36223558.

5. Mackiewicz J, Mackiewicz A. Programmed cell death 1 checkpoint inhibitors in the treatment of patients with advanced melanoma. *Contemp Oncol*. 2017;21(1):1–5. <https://doi.org/10.5114/wo.2017.66651>.
6. Yost KE, Satpathy AT, Wells DK, Qi Y, Wang C, Kageyama R, et al. Clonal replacement of tumor-specific T cells following PD-1 blockade. *Nat Med*. 2019;25:1251–9.
7. Waterhouse DM, Garon EB, Chandler J, McCleod M, Hussein M, Jotte R, et al. Continuous Versus 1-Year Fixed-Duration Nivolumab in Previously Treated Advanced Non–Small-Cell Lung Cancer: CheckMate 153. *J Clin Oncol*. 2020;38(33):3863–73. <https://doi.org/10.1200/JCO.20.00131>.
8. Brahmer JR, Drake CG, Wollner I, Powderly JD, Picus J, Sharfmanet WH, et al. Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates. *J Clin Oncol*. 2010;28:3167–75. <https://doi.org/10.1200/JCO.2009.26.7609>.
9. Peer CJ, Goldstein DA, Goodell JC, Nguyen R, Figg WD, Ratain MJ. Opportunities for using in silico-based extended dosing regimens for monoclonal antibody immune checkpoint inhibitors. *Br J Clin Pharmacol*. 2020;86(9):1769–77. <https://doi.org/10.1111/bcp.14369>.
10. Ratain MJ, Goldstein DA. Time is money : optimizing the scheduling of Nivolumab. *J Clin Oncol*. 2018. <https://doi.org/10.1200/JCO.18.00045>.
11. Renner A, Burotto M, Rojas C. Immune checkpoint inhibitor dosing: can we go lower without compromising clinical efficacy? *J Global Oncol*. 2019;5:1–5. <https://doi.org/10.1200/JGO.19.00142>.
12. Louedec FL, Leenhardt F, Marin C, Chatelut E, Evrard A, Ciccolini J. Cancer immunotherapy dosing: a pharmacokinetic/Pharmacodynamic perspective. *Vaccines*. 2020;8(4):632. <https://doi.org/10.3390/vaccines8040632>.
13. Bantia S, Choradia N. Treatment duration with immune-based therapies in Cancer: an enigma. *J ImmunoTher Cance*. 2018;6:143.
14. Verma V, Sprave T, Haque W, Simone CB, Chang JY, Welsh JW, et al. A systematic review of the cost and cost-effectiveness studies of immune checkpoint inhibitors. *Immunother Cancer*. 2018;6(1):128. <https://doi.org/10.1186/s40425-018-0442-7>.
15. Korn EL, Freidlin B. Interim monitoring for non-inferiority trials: minimizing patient exposure to inferior therapies. *Ann Oncol*. 2018;29(3):573–7. <https://doi.org/10.1093/annonc/mdx788>.
16. Vasudev NS, Ainsworth G, Brown S, Pickering L, Waddell TS, Fife K, et al. LBA29 Nivolumab in combination with alternatively scheduled Ipilimumab in first-line treatment of patients with advanced renal cell carcinoma: a randomized phase II trial (PRISM). *Annals Oncol*. 2021;32(Supplement 5):S1304–305. <https://doi.org/10.1016/j.annonc.2021.08.2105>. ESMO Meeting.
17. Tachiki L, et al. Extended duration of anti-PD-1 therapy, using reduced frequency dosing, in patients with advanced melanoma and Merkel cell carcinoma. *J Clin Oncol*. 2022;40(16_suppl):2588–2588. ASCO Meeting.
18. Ward MC, Shah C, Adelstein DJ, et al. Cost-effectiveness of nivolumab for recurrent or metastatic head and neck cancer. *Oral Oncol*. 2017;74:49–55.
19. Zhang C, Zhang J, Tan J, Tian P, Li W. Cost-effectiveness of pembrolizumab for the treatment of non–small-cell lung cancer: a systematic review. *Front Oncol*. 2022;12:815587. <https://doi.org/10.3389/fonc.2022.815587>.
20. Qiao N N, Insinga R R, de Lima Lopes Junior G, Cook J, Sénécal M. A review of cost-effectiveness studies of pembrolizumab regimens for the treatment of advanced non-small cell lung cancer. *Pharmacoecon Open*. 2021;5(3):365–83.
21. Patil MV, Noronha V, Menon N, Rai R, Bhattacharjee A, Singh A, et al. Low-dose immunotherapy in head and neck cancer: a randomized study. *J Clin Oncol*. 2022;41(2):222–32. <https://doi.org/10.1200/JCO.22.01015>.
22. Gordon N, Stemmer SM, Greenberg D, Goldstein DA. Trajectories of injectable cancer drugs costs after launch in the United States. *J Clin Oncol*. 2018;36(4):319–25. <https://doi.org/10.1200/JCO.2016.72.2124>.
23. Leighl NB, Nirmalakumar S, Ezeife DA, Gyawali B. An arm and a leg: the rising cost of cancer drugs and impact on access. *Am Soc Clin Oncol*. 2021;41:1–12 Educ Book.
24. Mitchell AP, Goldstein DA. Cost savings and increased access with ultra-low-dose immunotherapy. *J Clin Oncol*. 2022. <https://doi.org/10.1200/JCO.22.01711>.
25. Patel A, Goldstein DA, Tannock IF. Improving Access to immunotherapy in low and middle-income countries. *Ann Oncol*. 2022;33:360–1.
26. Champiat S, Lambotte O, Barreau E, Belkhir R, Berdelou A, Carboneel F, et al. Management of immune checkpoint blockade dysimmune toxicities: a collaborative position paper. *Ann Oncol*. 2016;27:559–74. <https://doi.org/10.1093/annonc/mdv623>.
27. Johnson DB, Nebhan CA, Moslehi JJ, Balko JM. Immune-checkpoint inhibitors: long-term implications of toxicity. *Nat Rev Clin Oncol*. 2022;19(4):254–67. <https://doi.org/10.1038/s41571-022-00600-w>.
28. Koch L, Bertram H, Eberle A, Holleczeck B, Schmid-Hopfner S, Waldmann A, et al. Fear of recurrence in long-term breast cancer survivors—still an issue. Results on prevalence, determinants, and the association with quality of life and depression from the cancer survivorship—a multi-regional population-based study. *Psychooncology*. 2014;23(5):547–54.
29. Simard S, Thewes B, Humphris G, Dixon M, Hayden C, Mireskandari S, et al. Fear of cancer recurrence in adult cancer survivors: a systematic review of quantitative studies. *Cancer Surviv*. 2013;7(3):300–22. <https://doi.org/10.1007/s11764-013-0272-z>.

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Ready to submit your research? Choose BMC and benefit from:

- fast, convenient online submission
- thorough peer review by experienced researchers in your field
- rapid publication on acceptance
- support for research data, including large and complex data types
- gold Open Access which fosters wider collaboration and increased citations
- maximum visibility for your research: over 100M website views per year

At BMC, research is always in progress.

Learn more biomedcentral.com/submissions

